VDR and chronic kidney disease: This insight gains practical significance in experimental models of chronic renal failure (CRF), where VDR agonists like paricalcitol and calcitriol have demonstrated remarkable anti-fibrotic effects, offering a therapeutic window (Martínez-Arias et al., 2021).